Medication info

Empagliflozin/Metformin Film-Coated Tablet 5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Aju Pharmaceuticals Co., Ltd.
Appearance
Yellow, oval, biconvex, film-coated tablet with a brown tint
Packaging
10 tablets/box [10 tablets/PTP*1], 60 tablets/box [10 tablets/PTP*6], 60 tablets/bottle
Approval status
Active

MFDS item code 202201403 · Approved 2022.04.04

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each ingredient: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines, such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be given as this medicine is 1000 mg, which may be administered as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients in Whom the Medicine Is Contraindicated, item 2)). Older patients In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.

Ingredients

Manufacturer
Aju Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes with poor blood sugar control
  • cardiovascular disease
View approved original text

This medication contains empagliflozin and metformin, and is used in conjunction with diet and exercise therapy to help adult patients with type 2 diabetes manage their blood sugar levels. It is particularly effective for patients whose blood sugar is not adequately controlled, and those with cardiovascular disease should consult a specialist before use. This medication improves blood sugar management and aids in diabetes treatment.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each ingredient: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines, such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be given as this medicine is 1000 mg, which may be administered as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients in Whom the Medicine Is Contraindicated, item 2)). Older patients In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.

Precautions

This medication is used to control blood sugar levels and can cause a rare side effect known as severe lactic acidosis, so caution is advised. Lactic acidosis is a dangerous condition caused by an excessive buildup of lactic acid in the body and can occasionally lead to death. Additionally, taking this medication with insulin or sulfonylureas may increase the risk of hypoglycemia. Patients with allergies to any of the components should not take this medication, nor should patients with severely impaired kidney function. This medication should also be avoided in situations where acute worsening of kidney function is anticipated, such as severe infections, dehydration, heart attack, or shock. It is not administered to patients with type 1 diabetes or anyone with a history of lactic acidosis or diabetic ketoacidosis. Moreover, it should be discontinued prior to and post any radiographic contrast examinations in patients with acute heart failure. It is safest not to take this medication during pregnancy or while breastfeeding. Regular renal function tests must be conducted during treatment, and if kidney function worsens, the medicine should be discontinued. Caution is also needed for patients with a risk of fluid loss or those who have irregular meals and engage in vigorous exercise. This medication can cause gastrointestinal disturbances, urinary tract infections, genital infections, increased urination, hypoglycemia, among other side effects. Especially when taken with insulin or sulfonylureas, the risk of hypoglycemia may increase, hence monitoring blood glucose is crucial. Alcohol intake can heighten the risk of lactic acidosis, so it should be avoided during treatment. If surgery is planned or there are severe infections or trauma, the medication should be temporarily discontinued until the patient's condition improves. Extra caution should be taken when administering this medication to the elderly in relation to renal function decline and fluid loss risks. In the event of overdose, severe side effects such as lactic acidosis can arise; thus, it is imperative to adhere strictly to prescribed dosages. Safety and efficacy have not been established for children, hence it is not recommended for those under 18. If during treatment any symptoms like fever, genital or perineal pain, swelling, or rash occur, immediate contact with healthcare professionals is advised. Lastly, this medication may interact with various drugs, so it is vital to inform healthcare professionals if other medications are being taken. Finally, this medication should be stored out of reach of children and kept in its original container.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • decreased appetite
  • constipation
Show 180 more
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • urticaria
  • erythema and angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
  • perineal necrosis
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • gastritis
  • abdominal discomfort
  • anal incontinence
  • dry mouth
  • gastrointestinal disorder
  • gastroesophageal reflux disease
  • oral discomfort
  • salivary gland pain
  • headache
  • sensory impairment
  • postural dizziness
  • dizziness
  • drowsiness
  • weakness
  • chest discomfort
  • chest pain
  • fever
  • facial swelling
  • chills
  • strange sensation
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • weight loss
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • diplopia
  • hypertension
  • insomnia
  • constipation
  • nasopharyngitis
  • herpes zoster
  • anxiety
  • otalgia
  • postural vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscular weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal abrasion
  • macular fibrosis
  • ocular discomfort
  • conjunctival congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • operculated retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • persistent cough
  • allergic rhinitis
  • retained sputum
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open eye injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • cervical inflammation
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • vaginal discharge
  • hyperglycemia
  • decreased appetite
  • obesity
  • snoring
  • hyponatremia
  • dyslipidemia
  • diabetes
  • drowsiness
  • facial paralysis
  • memory impairment
  • neuralgia
  • Parkinson's disease
  • polyneuropathy
  • sensory disorders
  • CNS origin vertigo
  • fatigue
  • peripheral edema
  • facial edema
  • peripheral swelling
  • chills
  • strange sensation
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • postural vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. Additionally, it should be kept in a location that avoids extreme temperatures, ideally at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow, oval, biconvex, film-coated tablet with a brown tint

Package unit

10 tablets/box [10 tablets/PTP*1], 60 tablets/box [10 tablets/PTP*6], 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.